Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understoo...
| Main Authors: | , |
|---|---|
| 格式: | Journal article |
| 語言: | English |
| 出版: |
2013
|